Sanofi lifts expectations for 2026 sales growth, looks to M&A
The French drugmaker raised sales and profit forecasts after Dupixent beat expectations and said larger acquisitions may be needed to fill its pipeline.
- On Friday, Sanofi raised its annual sales growth forecast to a "low-teens percentage," up from 10%, banking on strong demand for its blockbuster asthma drug Dupixent.
- The company reported third-quarter business operating income of €5.43 billion, exceeding analyst expectations of €4.32 billion, with total sales reaching €14.44 billion, up 14.3% at constant exchange rates.
- CEO Belen Garijo, who began a strategic review in May, confirmed dealmaking is critical to replenishing the drug pipeline following trial setbacks last year.
- CFO François Roger said the company has about €20 billion in deal-making firepower and will pursue acquisitions larger than its historical €2 billion to €5 billion range.
- Analysts believe M&A is necessary to secure experimental drugs before 2027, when late-stage trial data is expected, as Sanofi seeks to maintain profitable growth.
13 Articles
13 Articles
Sanofi Raises Profit Forecast on Blockbuster Dupixent Sales
Sanofi weighs M&A opportunities to replenish pipeline, lifts 2026 growth targets - Regional Media News
By Bhanvi Satija LONDON, Oct 30 (Reuters) - French drugmaker Sanofi said on Friday that dealmaking will be an important part of replenishing the company's drug pipeline under new CEO Belen Garijo, following a series of trial setbacks last year. Chief Financial Officer François Roger [...]
Sanofi lifts expectations for 2026 sales growth, looks to M&A
By Bhanvi Satija LONDON, Oct 30 (Reuters) - French drugmaker Sanofi said on Friday it expects sales to grow by a "low-teens percentage" this year, up from a previous forecast of 10% sales growth, banking on strong demand for its blockbuster asthma dr...
Starbucks anticipates higher profits thanks to remediation successes +++ BYD's profit is growing slower than expected +++ Eli Lilly benefits from the weight loss boom +++ The newsblog.
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
